# Baxalta now part of Shire clinical trials: 111 (2026)

ClinicalTrials.gov lists 111 trials with Baxalta now part of Shire as lead sponsor, 0 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Baxalta now part of Shire: 111 rows for $5.55, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/baxalta-now-part-of-shire

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 111
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 111, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 2, 2021 | NCT04985682 | A Study of ADVATE in People With Hemophilia A in India | Baxalta now part of Shire | Phase 4 | Completed | Hemophilia A | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04985682) |
| October 8, 2020 | NCT04578535 | A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant... | Baxalta now part of Shire | Phase 1 | Completed | Healthy Volunteers | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04578535) |
| May 19, 2020 | NCT04394286 | A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects | Baxalta now part of Shire | Phase 1/2 | Terminated | Hemophilia B | 2 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04394286) |
| April 15, 2020 | NCT04346108 | A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases... | Baxalta now part of Shire | Phase 3 | Completed | Primary Immunodeficiency Diseases (PID) | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04346108) |
| November 12, 2019 | NCT04158934 | A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A | Baxalta now part of Shire | Observational | Active not recruiting | Hemophilia A | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04158934) |
| March 18, 2019 | NCT03879135 | A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD) | Baxalta now part of Shire | Phase 3 | Completed | Von Willebrand Disease (VWD) | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03879135) |
| October 23, 2018 | NCT03716700 | Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN) | Baxalta now part of Shire | Observational | Completed | Primary Immunodeficiency Diseases (PID) | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03716700) |
| June 21, 2018 | NCT03565237 | RIXUBIS PMS India (RIXUBIS PMS) | Baxalta now part of Shire | Phase 4 | Completed | Hemophilia B | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03565237) |
| May 9, 2018 | NCT03519672 | Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic... | Baxalta now part of Shire | Observational | Completed | Congenital Thrombotic Thrombocytopenic Purpura | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03519672) |
| January 9, 2018 | NCT03393975 | A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) | Baxalta now part of Shire | Phase 3 | Completed | Thrombotic Thrombocytopenic Purpura (TTP) | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03393975) |
| December 12, 2017 | NCT03370172 | A Study of BAX 888 in Male Adults With Severe Hemophilia A | Baxalta now part of Shire | Phase 1/2 | Completed | Hemophilia A | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03370172) |
| September 11, 2017 | NCT03277313 | Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects | Baxalta now part of Shire | Phase 3 | Completed | Primary Immunodeficiency Diseases (PID) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03277313) |
| June 27, 2017 | NCT03199794 | Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice | Baxalta now part of Shire | Observational | Completed | Acquired Hemophilia A | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03199794) |
| June 14, 2017 | NCT03185897 | Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia | Baxalta now part of Shire | Observational | Completed | Hemophilia A, Hemophilia B | 242 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03185897) |
| April 17, 2017 | NCT03116347 | Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects | Baxalta now part of Shire | Phase 4 | Completed | Primary Immunodeficiency Diseases (PID) | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03116347) |
| February 15, 2017 | NCT03054389 | Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009-101 Study Through Patient... | Baxalta now part of Shire | Observational | Completed | Hemophilia B | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03054389) |
| November 7, 2016 | NCT02956122 | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD | Baxalta now part of Shire | Phase 2/3 | Terminated | Graft Versus Host Disease | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02956122) |
| November 4, 2016 | NCT02955355 | Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP | Baxalta now part of Shire | Phase 3 | Completed | Chronic Inflammatory Demyelinating Polyradiculoneuropathy | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02955355) |
| October 19, 2016 | NCT02937831 | RIXUBIS Drug Use-Result Survey (Japan) | Baxalta now part of Shire | Observational | Completed | Hemophilia B | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02937831) |
| October 13, 2016 | NCT02932618 | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD) | Baxalta now part of Shire | Phase 3 | Completed | Von Willebrand Disease | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02932618) |
| October 4, 2016 | NCT02922231 | Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea | Baxalta now part of Shire | Observational | Completed | Hemophilia B | 57 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02922231) |
| September 12, 2016 | NCT02895945 | BAX 802 in CHA With Inhibitors | Baxalta now part of Shire | Phase 3 | Terminated | Hemophilia A | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02895945) |
| May 6, 2016 | NCT02764489 | FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) | Baxalta now part of Shire | Phase 3 | Completed | Hemophilia A or B With Inhibitors | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02764489) |
| March 30, 2016 | NCT02722304 | Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency | Baxalta now part of Shire | Phase 3 | Terminated | Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02722304) |
| March 23, 2016 | NCT02716194 | BAX 826 Dose-Escalation Safety Study | Baxalta now part of Shire | Phase 1 | Completed | Hemophilia A | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02716194) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 14 |
| Phase 1/2 | 8 |
| Phase 2 | 6 |
| Phase 2/3 | 13 |
| Phase 3 | 35 |
| Phase 4 | 14 |
| Not applicable | 2 |
| Observational | 19 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 90 |
| Terminated | 16 |
| Withdrawn | 2 |
| Active not recruiting | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hemophilia A | 40 |
| Hemophilia B | 17 |
| Primary Immunodeficiency Diseases | 14 |
| alpha 1-Antitrypsin Deficiency | 8 |
| von Willebrand Diseases | 5 |
| Factor 8 deficiency, acquired | 4 |
| Protein C Deficiency | 3 |
| Anemia, Sickle Cell | 2 |
| Purpura, Thrombocytopenic, Idiopathic | 2 |
| Blood Coagulation Disorders | 2 |
| Coagulation Protein Disorders | 2 |
| Hematologic Diseases | 2 |
| Hemorrhagic Disorders | 2 |
| Graft vs Host Disease | 2 |
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 2 |
| Purpura, Thrombotic Thrombocytopenic | 2 |
| Lupus Erythematosus, Systemic | 1 |
| Agammaglobulinemia | 1 |
| Glomerulonephritis, IGA | 1 |
| Mucocutaneous Lymph Node Syndrome | 1 |
| Immunologic Deficiency Syndromes | 1 |
| Dementia | 1 |
| Alzheimer Disease | 1 |
| Pain | 1 |
| Anemia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Internet service providers in the United States](https://specstream.ai/data/businesses/internet-service-providers/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Biotechnology companies in the United States](https://specstream.ai/data/businesses/biotechnology-companies/united-states)
- [Pan Asian restaurants in the United States](https://specstream.ai/data/businesses/pan-asian-restaurants/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
